Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Debra Hanks"'
Autor:
Apaar Sadhwani, Huang-Wei Chang, Ali Behrooz, Trissia Brown, Isabelle Auvigne-Flament, Hardik Patel, Robert Findlater, Vanessa Velez, Fraser Tan, Kamilla Tekiela, Ellery Wulczyn, Eunhee S. Yi, Craig H. Mermel, Debra Hanks, Po-Hsuan Cameron Chen, Kimary Kulig, Cory Batenchuk, David F. Steiner, Peter Cimermancic
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Both histologic subtypes and tumor mutation burden (TMB) represent important biomarkers in lung cancer, with implications for patient prognosis and treatment decisions. Typically, TMB is evaluated by comprehensive genomic profiling but this
Externí odkaz:
https://doaj.org/article/bb85166704e240079299ad3d736a4fbb
Autor:
Monika D. Polewski, Gitte B. Nielsen, Ying Gu, Aaron T. Weaver, Gavin Gegg, Siena Tabuena-Frolli, Mariana Cajaiba, Debra Hanks, Michael Method, Michael F. Press, Claudia Gottstein, Aaron M. Gruver
Publikováno v:
Applied immunohistochemistrymolecular morphology : AIMM. 30(4)
The objectives were to develop a standardized Ki-67 immunohistochemistry (IHC) method for precise, robust, and reproducible assessment of patients with early breast cancer, and utilize this assay to evaluate patients participating in the monarchE stu
Autor:
Isabelle Auvigne-Flament, Craig H. Mermel, Peter Cimermancic, David F. Steiner, Ellery Wulczyn, Trissia Brown, Cory Batenchuk, Vanessa Velez, Apaar Sadhwani, Kamilla Tekiela, Kimary Kulig, Chang Huang-Wei, Ali Behrooz, Eunhee S. Yi, Robert Findlater, Debra Hanks, Hardik Patel, Po-Hsuan Cameron Chen, Fraser Tan
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Both histologic subtypes and tumor mutation burden (TMB) represent important biomarkers in lung cancer, with implications for patient prognosis and treatment decisions. Typically, TMB is evaluated by comprehensive genomic profiling but this requires
Autor:
Dipeshkumar Jaiswal, Jiangdian Wang, Jonathan Juco, Ellie Corigliano, Malinka Jansson Ms, Nancy Zhang, Stephanie Waldroup, Mary J. Savage, Jared Lunceford, Kenneth Emancipator, Karina Kulangara, Debra Hanks, Supriya Shah, Lindsay Guerrero
Publikováno v:
Archives of Pathology & Laboratory Medicine. 143:330-337
Context.— Regulatory approval of pembrolizumab for treatment of gastric and gastroesophageal junction (G/GEJ) adenocarcinoma required a reproducible scoring method for use of programmed death ligand-1 (PD-L1) protein expression as a companion diagn
Autor:
William Richardson, Fred R. Hirsch, Amita Mistry, J. Andrew Williams, Ian McCaffery, Debra Hanks, James Novotny, Ming-Sound Tsao, Keith M. Kerr, Dave Stanforth, Malinka Jansson, Rasika Kalamegham, Kenneth Emancipator, Bharathi Vennapusa, Eric J. Rubin, Abigail McElhinny, Penny Towne, James Ranger-Moore, Karina Kulangara, Jill Walker, John W. Longshore, Steve Averbuch
Publikováno v:
Journal of Thoracic Oncology. 12:208-222
Introduction The Blueprint Programmed Death Ligand 1 (PD-L1) Immunohistochemistry (IHC) Assay Comparison Project is an industrial-academic collaborative partnership to provide information on the analytical and clinical comparability of four PD-L1 IHC
Autor:
Debra Hanks, Hardik Patel, Ali Behrooz, Eunhee S. Yi, Peter Cimermancic, Huan-Wei Chang, Kimary Kulig, Robert Findlater, Kamilla Tekiela, Vanessa Velez, Apaar Sadhwani, Cory Batenchuk
Publikováno v:
Journal of Clinical Oncology. 38:3122-3122
3122 Background: The current standard work-up for both diagnosis and predictive biomarker testing in metastatic non-small cell lung cancer (NSCLC), can exhaust an entire tumor specimen. Notably, gene mutation panels or tumor mutation burden (TMB) tes
Autor:
Monika Vilardo, Debra Hanks, Alexander Prenta, Peng Duan, Sharika Vasudevan, Darlene Krohn, Mai Nguyen, Christina Samathanam, Landry Nicholson-Legg, Aaron R. Ellison, Marko Srdanov
Publikováno v:
Cancer Research. 78:4517-4517
Background: Recent data have demonstrated the clinical efficacy of anti-PD-1/PD-L1 checkpoint inhibitors in non-small cell lung cancer (NSCLC), and approvals by regulatory authorities in first-line and second-line settings have followed. In selected
Publikováno v:
Cancer Research. 78:LB-218
Background: The clinically relevant and highly reproducible combined positive score (CPS) algorithm is used in conjunction with PD-L1 IHC 22C3 pharmDx for evaluation of programmed death ligand 1 (PD-L1) expression in gastric or gastroesophageal junct
Autor:
Lindsay Guerrero, Alex Posch, Matthew J. Marton, Jiangdian Wang, Debra Hanks, Josette Carnahan, Jared Lunceford, Kenneth Emancipator, Mary J. Savage, Scott W. Boyer, Karina Kulangara, Jonathan Juco, Scott K. Pruitt
Publikováno v:
Journal of Clinical Oncology. 36:4065-4065
4065Background: TPS, the percentage of viable tumor cells with partial or complete membrane staining at any intensity, has been invaluable for assessing PD-L1 expression in non–small cell lung canc...
Autor:
Emin Oroudjev, James Novotny, H. David Inzunza, Christine Phillips, Ilana Satnick, Dipeshkumar Jaiswal, Rose Ann De Los Santos, Rachel Cleveland, Therese Phillips, Debra Hanks, Hendrick McDonald, Swarnalatha Y. Reddy, Malinka Jansson, Adam Northrup, Coree Pierce, Bethany Wynne, Josette Carnahan, Dania Brooks, Clive R. Taylor, Josette William
Publikováno v:
Journal of Clinical Oncology. 35:e14585-e14585
e14585 Background: PD-L1 IHC 28-8 pharmDx is a qualitative assay developed by Agilent Technologies for the Autostainer Link 48 platform and is based on EnVision FLEX visualization technology and monoclonal rabbit anti-PD-L1, clone 28-8 antibody. The